Ser383
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser383  -  FANCG (human)

Site Information
DSSEPRFsPPPsPPG   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 454239

In vivo Characterization
Methods used to characterize site in vivo:
electrophoretic mobility shift ( 2 ) , mutation of modification site ( 1 , 2 ) , phospho-antibody ( 1 , 2 ) , western blotting ( 1 )
Disease tissue studied:
lymphoma ( 1 ) , B cell lymphoma ( 1 )
Relevant cell line - cell type - tissue:

Downstream Regulation
Effects of modification on FANCG:
activity, induced ( 2 )

References 

1

Wilson JB, et al. (2008) FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3. Oncogene 27, 3641-52
18212739   Curated Info

2

Mi J, et al. (2004) FANCG is phosphorylated at serines 383 and 387 during mitosis. Mol Cell Biol 24, 8576-85
15367677   Curated Info